Teva Pharmaceuticals Stock Price Prediction


Teva is an Israeli biopharmaceutical company, and it makes more generic drugs than any other company in the world.

The biopharmaceutical giant is also the 18th biggest drug maker in the world. Each year, they make about 76 billion pills. It is also one of the most important stocks on the market for controlling births. It has more than 500 generic drugs in its list of 3,600 medicines.

On this list are items for women’s health, like oral contraceptives and intrauterine contraceptives. In 2016, the company said that a generic version of the birth control pill Tri-Cyclen Lo would be coming out.

Back then, Janssen Pharmaceuticals sold $488 million worth of the non-generic tablet in the US every year, so TEVA went after them.

- Advertisement -

Through its subsidiaries, the company also makes ParaGard T-380A, which is the only intrauterine copper device that the FDA has approved for use. TEVA bought Barr Pharmaceuticals for a total of $9 billion in the past.

The subsidiary produced Plan B, also known as the morning-after pill. But in 2017, TEVA sold the well-known brand for $675 million to Kelso & Co. and Juggernaut Capital Partners.

In 2022, TEVA’s total sales were around $15 billion, down from a high of $22 billion in 2017. But even though the company’s income has gone down over the years, its value might indicate a chance to invest at a discount.

At 3.98 multiples, TEVA’s price-to-earnings ratio is quite low. The pharmaceutical giant didn’t make as much money as expected in the fourth quarter and reported a 5% drop in sales.

Officials at the company said that lower sales of Copaxone, Bendeka, Treanda, and respiratory products were to blame. It’s possible that the drop in COVID cases is linked to the drop in sales of respiratory products.

Just recently, the company said that it planned to make a copycat antidepressant to compete with Axsome’s pharmaceuticals. This could help it gain more ground in the industry. This shows how flexible the company can be when it comes to spreading its influence to other areas of the pharmaceutical industry.

Share This Article